Clinical Evaluation of Vedistry Shallaki + Tablets in the Management of Osteoarthritis
Bibliographic record
Abstract
Objective: To establish the efficacy and safety of Vedistry Shallaki + Tablet in the management of osteoarthritis (OA). Method: A randomized, double blind, active controlled, single center, clinical study was carried out in 300 osteoarthritic subjects to evaluate the efficacy and safety of Vedistry Shallaki + Tablet in relieving symptoms of moderate to mild OA. The efficacy and safety of Vedistry Shallaki + Tablet administration in a dose of 1 tablet twice daily for 90 days was directly compared with the selective COX-2 inhibitor, celecoxib given in a dose of 100 mg twice daily using total Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) score, pain score, functional ability score, visual analog scale (VAS) score and Lequesne functional index values. Results: The results of the study showed that Vedistry Shallaki + Tablet can provide significant improvement in relieving the symptoms and the pain associated with OA. Osteoarthritic subjects receiving Shallaki Plus reported statistically significant changes/decreases in their clinical symptoms and pain compared to those receiving Celecoxib. This was evident from significant changes in the total Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) score, pain score, functional ability score, visual analog scale (VAS) score and Lequesne functional index values at P < 0.05 level. Conclusion: Vedistry Shallaki + Tablet promises the beneficial effects for the treatment of osteoarthritis by controlling inflammatory responses as well as the pain without any adverse effects.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".